RNA
UNLOCKING
AND SMALL
MOLECULE
THERAPIES
We Are Mercury Bio
Sparked by scientific breakthroughs in genomic research, Mercury Bio is developing a next-generation biomolecular drug delivery platform.
RNA and small-molecule drugs can be delivered by our platform through highly specific cell targeting without creating an immune reaction. Our platform will allow drug developers to speed their products to market by reducing the obstacles and risks encountered by traditional drug delivery systems. Low cost, speed to market, and high targeting will, most importantly, dramatically improve patient outcomes.
Originally called Spartina Biotechnologies, our company changed its name to Mercury Bio in 2022 to reflect our rapidly increasing focus on molecular drug-delivery technologies. Like the Roman god, Mercury Bio aims to be a messenger and translator, delivering targeted genetic information to regulate events at the cellular level, translating disease into health.
Molecular Biophysics
Molecular Biology
Microbial Genetics
Biochemistry
Genetic & Bioinformatics
Computational & Statistical Science
Theoretical Biology
OUR SCIENTIFIC EXPERTISE
WE’RE DEVELOPING TECHNOLOGIES TO
CHANGE THE
NUMBERS
THE CHALLENGE:
How to deliver therapeutic molecules to specific cell targets without loss of potency while simultaneously reducing side effects?
THE SOLUTION:
With our proprietary chimeric extracellular vesicle technology, we have developed an advanced drug delivery system unlike any other.
Using a novel approach for drug encapsulation in natural nanoparticles, our yEV™ system can increase drug potency while simultaneously reducing side effects. It employs cell-specific targeting not feasible in artificial drug encapsulation systems.
In addition, the extracellular vesicles used in our system can be delivered by multiple routes—as an injectable, an aerosol, or even as a probiotic, thereby greatly enhancing the potentials for drug targeting efficiency.
The chimeric yEV™ system represents a next-generation drug delivery system in a scalable low-cost production platform that can rapidly address existing and emerging disease threats.
-
The first public presentation about our yEV™ tech took place at the 3rd Annual mRNA-Summit in Boston, MA at the end of July 2023.
Missed the mRNA Summit? Contact us via the form below and request a copy of the presentation summary.
OUR RESEARCH PARTNERS
Contact Mercury Bio
AWARDS & GRANTS
2023
Mercury Bio received the following grants from the New Mexico Economic Development Department:
NM Technology Readiness Grant
NM Business Startup Grant
